Cytoreductive Surgery and HIPEC Improve Survival in Gastric Cancer with Peritoneal Carcinomatosis
Author Information
Author(s): Tang Li, Mei Lie-Jun, Yang Xiao-Jun, Huang Chao-Qun, Zhou Yun-Feng, Yonemura Yutaka, Li Yan
Primary Institution: Zhongnan Hospital of Wuhan University
Hypothesis
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) is effective in treating gastric cancer with peritoneal carcinomatosis.
Conclusion
Cytoreductive surgery combined with HIPEC significantly prolongs survival in a rabbit model of gastric cancer with peritoneal carcinomatosis.
Supporting Evidence
- CRS + HIPEC extended overall survival by at least 15 days compared to CRS alone or control group.
- The median overall survival was significantly higher in the CRS + HIPEC group.
- Severe adverse events were recorded, but CRS + HIPEC showed acceptable safety.
Takeaway
This study shows that a special surgery combined with heated chemotherapy can help rabbits with stomach cancer live longer.
Methodology
42 male New Zealand rabbits were injected with VX2 tumor cells and randomized into control, CRS alone, and CRS + HIPEC groups to evaluate overall survival and other health parameters.
Limitations
The study was conducted on a rabbit model, which may not fully replicate human responses.
Participant Demographics
42 male New Zealand rabbits, body weight between 1.8-2.9 kg.
Statistical Information
P-Value
0.00
Confidence Interval
95% CI 21.8 - 26.2 d for control group, 95% CI 21.3 - 28.7 d for CRS group, 95% CI 34.6 - 45.4 d for CRS + HIPEC group.
Statistical Significance
p=0.00
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website